ArticleParasites & vectors2021
Assessment of Babesia bovis 6cys A and 6cys B as components of transmission blocking vaccines for babesiosis.
Article in Parasites & vectors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Exploring the landscape of Babesia bovis vaccines: progress, challenges, and opportunities.Parasites & vectors · 2023Pooled it
- Treatment Efficacy of Imidocarb Dipropionate in Saanen Goats Experimentally Infected withPathogens (Basel, Switzerland) · 2026Article
- Structural and antigenic characterization of Babesia Bovis HAP2 domains.Scientific reports · 2025Article
- The impact ofFrontiers in cellular and infection microbiology · 2025Article
- Current vaccines, experimental immunization trials, and new perspectives to control selected vector borne blood parasites of veterinary importance.Frontiers in veterinary science · 2024Review
- Vaccination of cattle with the Babesia bovis sexual-stage protein HAP2 abrogates parasite transmission by Rhipicephalus microplus ticks.NPJ vaccines · 2023Article
- Vaccination with anFrontiers in immunology · 2023Article
- Article
- Unraveling the Complexity of the Rhomboid Serine Protease 4 Family ofPathogens (Basel, Switzerland) · 2022Article
- Identification of novel immune correlates of protection against acute bovine babesiosis by superinfecting cattle withFrontiers in immunology · 2022Article
- Identification of CCp5 and FNPA as Novel Non-canonical Members of the CCp Protein Family inFrontiers in veterinary science · 2022Article
- A Culture-Adapted Strain ofFrontiers in cellular and infection microbiology · 2022Article
- Babesiosis as a potential threat for bovine production in China.Parasites & vectors · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundBabesia bovis reproduces sexually in the gut of its tick vector Rhipicephalus microplus, which involves expression of 6cys A and 6cys B proteins. Members of the widely conserved 6cys superfamily are candidates for transmission blocking vaccines (TBV), but intricacies in the immunogenicity of the 6cys proteins in the related Plasmodium parasites required the identification of transmission blocking domains in these molecules for vaccine design. Hereby, the immunogenic efficacy of recombinant (r) B. bovis 6cys A and B proteins as a TBV formulation was studied.
methodsThe immunogenicity of r6cys A and 6cys B proteins expressed in a eukaryotic system was evaluated in a cattle immunization trial (3 immunized and 3 control calves). A B. bovis sexual stage induction in vitro inhibition assay to assess the ability of antibodies to block the production of sexual forms by the parasite was developed.
resultsImmunized cattle generated antibodies against r6cys A and r6cys B that were unable to block sexual reproduction of the parasite in ticks. Additionally, these antibodies also failed in recognizing native 6cys A and 6cys B and peptides representing 6cys A and 6cys B functional domains and in inhibiting the development of sexual forms in an in vitro induction system. In contrast, rabbit antibodies generated against synthetic peptides representing predicted B-cell epitopes of 6cys A and 6cys B recognized recombinant and native forms of both 6cys proteins as well as peptides representing 6cys A and 6cys B functional domains and were able to neutralize development of sexual forms of the parasite in vitro.
conclusionsThese data, combined with similar work performed on Plasmodium 6cys proteins, indicate that an effective 6cys protein-based TBV against B. bovis will require identifying and targeting selected regions of proteins containing epitopes able to reduce transmission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.